A new government initiative promises to slash the time it takes for patients to get insurance coverage for breakthrough medical devices, shrinking what has often been a years-long wait to as little as two months. The program, announced jointly by the Centers for Medicare and Medicaid Services and the U.S. Food and Drug Administration, aims to remove one of the biggest barriers between life-saving innovation and the people who need it.
The initiative, called RAPID, which stands for Regulatory Alignment for Predictable and Immediate Device, aligns FDA reviews with CMS coverage decisions. This means that for the first time, insurance considerations will begin early in the development process, rather than after a device is already approved. Under the old system, a device could win FDA clearance but then face more than a year of uncertainty before Medicare and Medicaid decided whether to pay for it. The new pathway targets a turnaround of just two months. The program applies specifically to breakthrough technologies that address unmet medical needs and already qualify for faster FDA review.
Forty devices are already eligible for the program, and another 20 could potentially participate, according to the agencies. Examples include artificial heart valves, devices that correct heart rhythms, and implants that stimulate nerves to treat disease. These products are often developed by major medical technology companies such as Medtronic, Boston Scientific, and Abbott Laboratories. The previous system created a patchwork of access, where patients in some regions gained coverage quickly while others waited years. The new approach is designed to eliminate that inconsistency.
What This Means for Patients and Innovation
The core problem has been the so-called National Coverage Determination, the government’s formal decision on whether Medicare and Medicaid will pay for a device. While it does not legally bind private insurers, many follow the government’s lead. By bringing the insurance decision into the approval process, the new pathway could set a faster standard across the entire healthcare system. FDA Commissioner Marty Makary said in a statement that Americans deserve timely access to meaningful treatments without red tape or high costs.
Looking ahead, the success of the RAPID program will depend on how quickly the first devices move through the new pipeline and whether private insurers follow suit. For patients with conditions that currently have few good treatment options, the change represents a hopeful step toward faster, more equitable access to cutting-edge care. If the program works as designed, it could reshape how medical innovation reaches the bedside.